Lannett bought portfolio of generic products from Endo International

| By | Drug Manufacturing, Generics

Lannett Company announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International for an upfront payment plus future milestone payments.

The portfolio primarily consists of oral solutions with a few semi-solid products. For the 12 months ended March 2018, combined sales of the acquired products were in excess of $175 million, according to IMS.

The acquired portfolio of products will be manufactured at Lannett’s liquid generics facility in Carmel, New York, which has the capacity, capability and expertise.

Based in Philadelphia, USA, Lannett Company was founded in 1942. Company develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

Endo International is a generics and specialty branded pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997.

SOURCE: lannett
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.